Search results for " polymorphisms"

showing 10 items of 113 documents

Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research

2013

Background: Diagnostic imaging plays a relevant role in the care of patients with breast cancer (BC). Positron Emission Tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) has been widely proven to be a clinical tool suitable for BC detection and staging in which the glucose analog supplies metabolic information about the tumor. A limited number of studies, sometimes controversial, describe possible associations between FDG uptake and single nucleotide polymorphisms (SNPs). For this reason this field has to be explored and clarified. We investigated the association of SNPs in GLUT1, HIF-1a, EPAS1, APEX1, VEGFA and MTHFR genes with the FDG uptake in BC. Methods: In 26 caucasian individu…

OncologyCancer Researchmedicine.medical_specialtyPathologydbSNPGenotypePET-CTSingle-nucleotide polymorphismStandardized uptake valueBreast NeoplasmsGene mutationMultimodal ImagingPolymorphism Single NucleotideBreast cancerBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansPET-CTSUVpvcbiologybusiness.industryResearchGlucose analogSUVmaxSingle nucleotide polymorphismsmedicine.diseaseSingle nucleotide polymorphismBreast cancer Single nucleotide polymorphisms PET-CT SUVmax SUVpvcOncologyMethylenetetrahydrofolate reductasePositron-Emission Tomographybiology.proteinFemaleRadiopharmaceuticalsbusinessTomography X-Ray Computed
researchProduct

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

2018

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysi…

OncologyHepatocellular carcinomalaw.inventionLeukocyte Count0302 clinical medicineRandomized controlled trialNeutrophil-tolymphocyte ratiolawMedicineNeutrophil-to-lymphocyte ratioLiver NeoplasmsGastroenterologyMicroRNAGeneral MedicineSorafenibPrognosisTreatment OutcomeLiver030220 oncology & carcinogenesisHepatocellular carcinomaBiomarker (medicine)030211 gastroenterology & hepatologyAdverse events; Angiopoietin; Biomarker; Hepatocellular carcinoma; MicroRNA; Neutrophil-tolymphocyte ratio; Polymorphisms; Sorafenib; Vascular endothelial growth factor; Gastroenterologymedicine.drugAdverse eventSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsSingle-nucleotide polymorphismAngiopoietin03 medical and health sciencesInternal medicineBiomarkers TumorHumansNeoplasm InvasivenessPolymorphismNeutrophil to lymphocyte ratioAdverse effectbusiness.industryBiomarkermedicine.diseasedigestive system diseasesClinical Trials Phase III as TopicDrug Resistance NeoplasmAdverse eventsEtiologyVascular endothelial growth factorbusinessPolymorphisms
researchProduct

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

2015

OBJECTIVE: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled.DESIGN: To show a HR advantage of 0.6 in progression-free survival (PFS) for FCGR2A-HH versus the rest and FCGR3A-VV versus the rest, with an 80% power, 80 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type (KRAS-WT) and 52 KRAS-WT patients are required, respectively. This leads to a total sample size of 952 and 619 patients, respectively. Samples were collected from 1123 mCRC patients from 15 European centres treated wit…

OncologyMaleReceptors IgG/geneticsGenotyping TechniquesColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeGenetic PolymorphismsErbB Receptors/antagonists & inhibitorsNeoplasm MetastasisAntibody Targeted TherapyImmune ResponseAged 80 and overbiologyCetuximabGastroenterologyColorectal Neoplasms/drug therapyMiddle AgedErbB ReceptorsSurvival RateAntibodies Monoclonal Humanized/therapeutic useFemaleKRASAntibodyColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsAntibodies Monoclonal HumanizedDisease-Free SurvivalYoung AdultRefractoryInternal medicinemedicineHumansneoplasmsGerm-Line MutationAgedColorectal CancerChemotherapyPolymorphism Geneticbusiness.industryReceptors IgGAntineoplastic Agents/therapeutic usemedicine.diseasedigestive system diseasesOxaliplatinIrinotecanImmunologybiology.proteinbusinessGenotyping Techniques/standards
researchProduct

Association Between Interleukin-10 Polymorphisms and Alzheimer's Disease: A Systematic Review and Meta-Analysis

2012

UNLABELLED It has been hypothesized that polymorphisms of interleukin (IL)-10 genes affect the risk of developing late onset Alzheimer's disease (AD). However, results of different studies are often inconsistent. Our aim was to investigate by meta-analysis the association of the common polymorphisms comprehensively defining the genetic variability of the IL-10 gene with AD risk. Fifteen studies investigating the association between IL-10 polymorphisms (-1082, -819, -592) and AD were found and analyzed. The model-free approach was applied to meta-analyze these case-control genetic association studies. Available data suggested an association between -1082 polymorphism and AD risk with a margi…

Oncologymedicine.medical_specialtyAlzheimer’s disease IL-10 meta-analysis polymorphismsLower riskPolymorphism Single NucleotideAlzheimer DiseasePolymorphism (computer science)Internal medicineGenotypeHumansMedicineGenetic Predisposition to DiseaseGenetic variabilityGenetic Association StudiesGenetic associationSettore MED/04 - Patologia GeneraleGeneticsbusiness.industryGeneral NeuroscienceHaplotypeGeneral MedicineOdds ratioInterleukin-10Psychiatry and Mental healthClinical PsychologyMeta-analysisGeriatrics and GerontologybusinessJournal of Alzheimer's Disease
researchProduct

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk

2019

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male brea…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismPALB2Diseasemale breast cancerHyperestrogenismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerInternal medicineGenotypeCYP17A1Internal MedicineGenetic predispositionMedicine030212 general & internal medicineskin and connective tissue diseasesEstrogen Receptor Statusmale breast cancer; CYP17A1; CYP1B1; polymorphisms; male breast cancer risklcsh:RC648-665business.industryResearchmedicine.diseasemale breast cancer risk030220 oncology & carcinogenesisMale breast cancerCYP1B1medicine.symptombusinesspolymorphismsEndocrine Connections
researchProduct

Abstracts of the 3rd Joint Meeting of Pathology and Laboratory Medicine

2016

Background: Degenerative forms of mitral valve diseases (MVDs) are complex pathologies. Thus, it is difficult to make generalizations about MVD pathways or genetic risk factors. However, a key role of metalloproteinases (MMPs) in their pathophysiology is emerging. Thus, we performed a study to assess eventual associations of some functional SNPs in MMP-2 and MMP-9 genes with MVD risk, symptom severity and short- and long-term (4.8 years) complications. Methods: For this purpose, 90 patients and two control groups were genotyped for MMP-2 and MMP-9 gene SNPs, and systemic levels of proatrial natriuretic peptide (ANP), and two enzymes were quantified and correlated to the MMP-2 and MMP-9 SNPs…

Pathologymedicine.medical_specialtybusiness.industryMedical laboratorySettore MED/05 - Patologia ClinicaMedicineJoint (building)businessDegenerative Mitral Valve Disease MMP2 and 9 polymorphismsPathology and Forensic MedicineThe American Journal of Pathology
researchProduct

An innovative way to highlight the power of each polymorphism on elite athletes phenotype expression

2017

The purpose of this study was to determine the probability of soccer players having the best genetic background that could increase performance, evaluating the polymorphism that are considered Performance Enhancing Polymorphism (PEPs) distributed on five genes: PPAR alpha, PPARGC1A, NRF2, ACE e CKMM. Particularly, we investigated how each polymorphism works directly or through another polymorphism to distinguish elite athletes from non-athletic population. Sixty professional soccer players (age 22.5 +/- 2.2) and sixty healthy volunteers (age 21.2 +/- 2.3) were enrolled. Samples of venous blood was used to prepare genomic DNA. The polymorphic sites were scanned using PCR-RFLP protocols with …

PerformancePopulationlcsh:MedicinePolymerase chain reaction-restriction fragment length polymorphism; performance; performance-enhancing polymorphismsBiologyLogistic regressionArticlelcsh:QM1-69503 medical and health sciences0302 clinical medicineStatistical significanceGenotypeElite athletesOrthopedics and Sports MedicinePerformance-enhancing polymorphismeducationMolecular BiologyGeneticseducation.field_of_studylcsh:Rperformance-enhancing polymorphisms030229 sport sciencesCell Biologylcsh:Human anatomyPhenotypePolymerase chain reaction-restriction fragment length polymorphism performance-enhancing polymorphisms performanceAce polymorphismPolymerase chain reaction-restriction fragment length polymorphismPPARGC1ANeurology (clinical)human activities030217 neurology & neurosurgery
researchProduct

Polymorphisms of beta-lactoglobulin promoter region in three Sicilian goat breeds

2012

Several beta-lactoglobulin (BLG) polymorphisms have been described within the proximal promoter region and coding region of the caprine gene, although no genetic variants affecting the protein amino acid composition and/or expression level have been characterized so far. Binding sites for several transcription factors (TFs) are present in the BLG promoter region. The aims of this work were to sequence the full-length promoter region of three Sicilian goat breeds in order to identify polymorphisms, analyze the identified haplotypes, search for differences between breeds for the presence of polymorphisms in this gene region, search for putative TFs binding sites, and check if polymorphisms la…

SICILIAN GOATMolecular Sequence DataSNPSingle-nucleotide polymorphismLactoglobulinsBiologyPolymerase Chain ReactionPolymorphism Single NucleotideSettore AGR/17 - Zootecnica Generale E Miglioramento GeneticoSpecies SpecificityBETA LACTOGLOBULIN GENEGene expressionGeneticsAnimalsCluster AnalysisCoding regionBinding sitePromoter Regions GeneticSicilyMolecular BiologyGeneTranscription factorGeneticsBase SequenceModels GeneticGoatsHaplotypeGenetic VariationPromoterSequence Analysis DNAGeneral MedicineMilk ProteinsMolecular biologyNFI Transcription FactorsTRANSCRIPTION FACTORSBeta-lactoglobulin Polymorphisms Promoter Sicilian goatsHAPLOTYPES
researchProduct

Genetic diversity and phylogenetic relationships among four breeds reared in Sicily using β-lactoglobulin promoter region polymorphisms

2011

The aim of this work was to analyze the genetic diversity and the phylogenetic relationships among the Valle del Belice (VDB) breed and the other sheep breeds considered as ancestors, using -lactoglobulin (BLG) promoter region polymorphisms. The BLG promoter region of 50 randomly chosen animals from the four breeds (VDB n=20; Comisana (COM) n=10; Pinzirita (PIN) n=10; Sarda (SAR) n=10) were sequenced and aligned, and results showed the presence of 36 single nucleotide polymorphisms (SNPs) and one deletion. The number of polymorphic sites identified showed high variability within breeds. Nucleotide (π) and haplotype (Hd) diversity were estimated with DnaSP software, whereas PHASE software w…

Settore AGR/17 - Zootecnica Generale E Miglioramento Geneticob-Lactoglobulin Polymorphisms Sheep breeds Phylogenetic analysis
researchProduct

The Sicilian cattle breeds in a global context: genome-wide relationship with other worldwide cattle

2015

Genomic technologies, such as high-throughput genotyping based on Single Nucleotide Polymorphism (SNP) arrays, provide background information concerning genome structure in domestic animals. The aims of this study were to cluster animals, to explore the relationships among and within breeds, and to place the Sicilian breeds, Cinisara and Modicana, in a global context. The Illumina Bovine SNP50K v2 BeadChip genotyping data from 144 animals of Sicilian breeds and from other 1,543 animals belonging to 134 domesticated bovid breeds (DRYAD) were used. These breeds arose from 3 domesticated (sub)species: Bos javanicus, B. taurus indicus, and B. t. taurus. Principal Component Analysis (PCA) genera…

Settore AGR/17 - Zootecnica Generale E Miglioramento Geneticogenetic diversity genetic structure Sicilian cattle breeds single nucleotide polymorphisms
researchProduct